Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. - Wikidata - wikimedia - TriplyDB

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.

http://www.wikidata.org/entity/Q34728055

about

The use of lorcaserin in the management of obesity: a critical appraisal Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure Mechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in appetite regulation Obesity pharmacotherapy: current perspectives and future directions Structural Basis for Molecular Recognition at Serotonin Receptors Conformational analysis of the anti-obesity drug lorcaserin in water: how to take advantage of long-range residual dipolar couplings.Effects of anti-obesity drugs, phentermine and mahuang, on the behavioral patterns in Sprague-Dawley rat model.Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification High-fat and obesogenic diets: current and future strategies to fight obesity and diabetes.Directed evolution of RebH for site-selective halogenation of large biologically active molecules.Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.The use of serotonergic drugs to treat obesity--is there any hope?Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.The utility of animal models to evaluate novel anti-obesity agents.We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice Directly Observable Behavioral Effects of Lorcaserin in Rats Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys.Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.Lorcaserin for the treatment of obesity Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity.New therapeutic potential for psychoactive natural products.5-HT2C receptor modulators: a patent survey.Approaches to the pharmacological treatment of obesity.Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.The safety and efficacy of lorcaserin in the management of obesity.Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial.Safety and tolerability review of lorcaserin in clinical trials.Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue.Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.Lorcaserin for the treatment of obesity? A closer look at its side effects.Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist.Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating.Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.

P2860

Q24594774-1D1FC8B5-92F5-42AD-95BA-27DA2B288D1E Q24611940-C059B655-755E-4B4B-928D-05B75DDC9F75 Q26749523-54F92142-6FF5-4B2C-ABBF-AC97A6133115 Q26828559-E6B7782E-198B-483B-9D07-75E5C9D2409B Q27676926-0218026B-F447-4EE0-9977-40CE3A7F2A90 Q30672639-8E8910A2-8A4E-4071-ADF6-75043355FD6F Q33838889-B3193D90-476F-4A2D-96E3-554D696B1CC2 Q34207033-A93DD122-1118-40B4-8DA5-4DEFD14E9838 Q34212924-29FE7CF9-CD64-4D58-A466-B564E27403EE Q34462524-23D91279-8BBE-4966-A6A1-B79C7E65D8E4 Q34659424-E48E5735-33B6-43E3-952B-18E984D25B41 Q34712327-F7FAC358-313D-4BD2-B5C7-BF6A77C69CF1 Q34962263-A82635B8-7461-4072-9DF7-F8114E7437A7 Q35049574-4A3B1C03-8C76-4497-BAE1-A7FFC19FA1F0 Q35188133-3785F3ED-C31B-4E72-AFCE-003E5698C682 Q35589958-AF2A8C23-6172-4EFE-9026-AAFCB432EB3E Q35823591-5E0B3EDE-0374-4D30-A724-0D42BAE031AF Q35837700-620BAF45-8B4F-4EC0-8F57-D568E546A88F Q36244665-7AF837ED-549E-42E6-AA29-DC7782AF558D Q36316458-FEAEB0F0-7060-4689-87AD-F4F52B8E935C Q36432310-183ED415-4434-4DA0-A636-C8C285E7B2B4 Q36540945-92728C75-CAB0-48B5-804D-5AB7B36DE736 Q36777115-28AD5AC1-F265-4DD6-B38E-82BF4CF70E69 Q37172259-E45DD772-E71D-4C9B-968D-4AEE09703A83 Q37310802-70ECD7AF-91A0-49D0-BF8B-21DAB4E482C9 Q37660087-EC7B50DB-6560-4CF5-ADD6-9177E3B965EB Q37789738-B6050F1C-196E-42C6-9D7E-84E35B152205 Q37960073-C2BA7D53-46AE-4D9B-BF80-6896EE1A1F82 Q38031743-11335AD4-5AB7-43E6-80B2-156D1E798027 Q38160636-811B2033-3318-4F53-856D-FBEACD63D780 Q38385068-D1EBF119-BAEE-408F-B8C4-297F220E3E9C Q38954263-564E526D-6547-48A3-84CE-C9C9A1BEEE0B Q39298178-96114396-FE00-4FC9-9737-8738A898C2A2 Q39768889-E330647A-0A01-4B08-A5C7-AF6171BC5101 Q41910031-75DB932A-04EE-435B-93EE-82B541EBAE05 Q42957301-AB1BCCBF-D028-4845-B8BF-52409FA31BA1 Q45908028-415E7080-97BF-4592-BE7F-40B754604546 Q46213450-25A716AF-E6F7-4509-AE76-5C45AE8C0AE0 Q47172455-B4060317-E440-45BB-8EF8-78C030B9D828 Q47588598-174D3C22-A98B-452F-A249-608B7CD6BCF1

P2860

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.

http://www.wikidata.org/entity/Q34728055

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Discovery and structure-activi ...... for the treatment of obesity.

@ast

Discovery and structure-activi ...... for the treatment of obesity.

@en

Discovery and structure-activi ...... for the treatment of obesity.

@nl

type

label

Discovery and structure-activi ...... for the treatment of obesity.

@ast

Discovery and structure-activi ...... for the treatment of obesity.

@en

Discovery and structure-activi ...... for the treatment of obesity.

@nl

prefLabel

Discovery and structure-activi ...... for the treatment of obesity.

@ast

Discovery and structure-activi ...... for the treatment of obesity.

@en

Discovery and structure-activi ...... for the treatment of obesity.

@nl

P1433

Q34728055-1B4065E1-B85D-4326-920D-1794F340E76F

P1476

Q34728055-A50FE0A2-89DC-4FB2-9CE4-8F2A83444B33

P2093

Q34728055-0CEF03AF-0601-4AA8-B1CD-075D59B19568

Q34728055-18E90EC8-3135-43AF-B81F-4FC723BFC94B

Q34728055-4C4777F4-E9A0-4FC7-936A-C94841B13080

Q34728055-4E1303AA-0AA3-43A7-AFEC-DD7761106AF8

Q34728055-578ED0DA-3452-48DB-B993-0419AC3897FF

Q34728055-5F11F353-EB22-40B5-BF17-21ABB54D33BE

Q34728055-5F24B9FC-C22C-4079-8D8D-08E881492334

Q34728055-7613CF83-C7BC-42B1-A92C-21B4CF7586A0

Q34728055-7B9F641D-D2BA-4DF8-9ACE-F61819FB0DC8

Q34728055-7FF5E68A-88FB-466B-86FB-3C659598CF22

P304

Q34728055-2E44321B-53BE-406C-BAE8-DF8C5074C60C

P31

Q34728055-CF2BB1B2-95BD-4211-8D60-2764D4C96336

P356

Q34728055-1C8B30BA-60F8-419C-B799-28812E4AB24D

P407

Q34728055-DAF47267-749E-41A1-B4D3-8648ADD5418F

P433

Q34728055-548ECC9D-9526-45B6-8158-362B130871B2

P478

Q34728055-081529D9-690B-4D15-A42F-E55B9E9DA468

P50

Q34728055-A9A631DB-5240-4803-A1A8-87F0E10356DF

P577

Q34728055-684A33C2-DE5C-47F5-B45E-5B84A9955950

P698

Q34728055-A0C18ECA-EE11-445A-97BC-95C964C7139C

P921

Q34728055-613a6712-4ab9-4992-90ea-9494aaca2251

Q34728055-F8D48726-2538-48E8-B147-5C1545656D6F

Q34728055-FECFCE50-7444-4B29-B25B-1F6401C2CC83

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery and structure-activi ...... for the treatment of obesity.

@en

P2093

Albert Ren

http://www.w3.org/2001/XMLSchema#string

Andrew J Grottick

http://www.w3.org/2001/XMLSchema#string

Brian M Smith

http://www.w3.org/2001/XMLSchema#string

Charlemagne S Gallardo

http://www.w3.org/2001/XMLSchema#string

Charles A Gilson

http://www.w3.org/2001/XMLSchema#string

Christina Bjenning

http://www.w3.org/2001/XMLSchema#string

Dipanjan Sengupta

http://www.w3.org/2001/XMLSchema#string

Douglas M Park

http://www.w3.org/2001/XMLSchema#string

Emily B Prieto

http://www.w3.org/2001/XMLSchema#string

Frederique Menzaghi

http://www.w3.org/2001/XMLSchema#string

P304

305-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM0709034

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18095642

http://www.w3.org/2001/XMLSchema#string

P921

lorcaserin hydrochloride hemihydrate